

# MARKET REPORT



India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there

Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have been a new generation of entrepreneurs who have ventured into the drug discovery path backed by VC funding and no pharma heritage ! In this Outlook we highlight the names of some select innovation/drug discovery companies who have successfully raised funds to sustain the research, out-licensed some of their assets or are likely to do so in the next 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand the universe further.

## Additional Details

**Publisher :** MP Advisors

**Reference :** 4476

**Number of Pages :** 22

**Report Format :** PDF

**Publisher Information :**



**MP Advisors**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there [Published by MP Advisors]

- Company Analysis : Connexious - Connexios has had a bumpy ride like most Rising stars/drug discovery companies in the biotech sector• Technology Platform• Therapy Focus—Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)• Key Milestones• Figure 1: PRODUCTS IN PIPELINE- DIABETES• Figure 2: PRODUCTS IN PIPELINE FOR NASH• Figure 3: OTHER PROGRAMS• Appendix 1: Network Biology Platform for Diabetes and fibrosis• Appendix:2 Novel GPR40 agonist• CNX-103: Whole body improvement of metabolic health• Table 1: Differences Between G-Protein Coupled receptor agonists• Table 2: Pipeline Of Gpr Agonist For Treatment Of Type 2 DiabetesCellworks - Cellworks (CW) has evolved from a service based company to a drug discovery /development company on the strength of its proprietary Virtual Prototyping platform that allows simulation of cell types//disease in silico. • Technology Platform • Pipeline • Figure 1: Simulation Based personalization• Figure 2: Cellworks Therapeutic ProgramsBugworks - Bugworks is a validation of Cellworks simulation in silico Technology Platform where its Bugworks Microbial Platform (BMP) combines functional proteomics with sophisticated semiconductor designe engineering to model and manipulate various bacterial systems. • Therapy focus- Serious Hospital Infection• Technology Platform• Need of the Hour- New Targets= New Antibiotic Class• The GAIN Act• Figure 1: Drug Development Success For Tb• Figure 2: Going Way Froward : focus: Helathcare Associated InfectionsTergene - Tergene’s first product in development is a vaccine for pneumonia caused by, Streptococcus pneumonia (pneumococcus). The available vaccine The Pneumococcal Polysaccharide Vaccines (PPV)• Development Strategy and Status-• Long term plans-• Vaccine Market-• Figure 1: sales of currently available vaccines for streptococcus pneumonia• Figure 2: Ww Demand Forecast Of Vaccines For Streptococcus Pneumonia• Figure 3: Vaccine Market

# How to Buy...

India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there [Published by MP Advisors]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/20121>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Price:**

\$850 | Price

**Payment Options:** (please tick one)

**Online Credit Card** (we will email you the invoice with a payment link)

**Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.